First In Class News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call was held 28 September 2023 at 8:00 AM EST (10:00 PM AEST). Please click on the link to watch the replay: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 29, 2023 /PRNewswire/ Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced pos

San diegoUnited statesUnited kingdomUniversity of california san diegoSouth australiaSpyros papapetropoulosMurrayb steinPrnewswire bionomics limited nasdaqMerck co incAffairs san diego healthcare systemBionomics or companyPublic healthDrug administrationMontgomery sberg depression rating scaleInsomnia severity indexSheehan disability scale